<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28327172</article-id><article-id pub-id-type="pmc">5361822</article-id><article-id pub-id-type="publisher-id">1877</article-id><article-id pub-id-type="doi">10.1186/s13063-017-1877-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Effect of Guizhifulingwan (Keishibukuryogan) on climacteric syndrome: study protocol for a randomized controlled pilot trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jung-Eun</given-names></name><address><email>eujuki@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Junghyo</given-names></name><address><email>choajoa@dju.kr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kwon</surname><given-names>Ojin</given-names></name><address><email>cheda1334@kiom.re.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Ae-Ran</given-names></name><address><email>arkim@kiom.re.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Hyo-Ju</given-names></name><address><email>mable@kiom.re.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>So-Young</given-names></name><address><email>syjung@kiom.re.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Joo-Hee</given-names></name><address><email>jhkim714@kiom.re.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Mikyung</given-names></name><address><email>mkkim@kiom.re.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Hye-Yoon</given-names></name><address><email>letter.dr.lee@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5730-6869</contrib-id><name><surname>Lee</surname><given-names>Jun-Hwan</given-names></name><address><email>omdjun@kiom.re.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8749 5149</institution-id><institution-id institution-id-type="GRID">grid.418980.c</institution-id><institution>Clinical Research Division, </institution><institution>Korea Institute of Oriental Medicine, </institution></institution-wrap>1672 Yuseongdae-ro, Yuseong-gu, Daejeon 34054 Republic of Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.459450.9</institution-id><institution>Department of Internal Korean Medicine, </institution><institution>Daejeon Oriental Hospital of Daejeon University, </institution></institution-wrap>176-9, Daeheung-ro, Jung-gu, Daejeon 34929 Republic of Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1791 8264</institution-id><institution-id institution-id-type="GRID">grid.412786.e</institution-id><institution/><institution>University of Science &#x00026; Technology (UST), Korean Medicine Life Science, </institution></institution-wrap>Daejeon, 34054 Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>135</elocation-id><history><date date-type="received"><day>7</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The aim of this study is to explore the efficacy of Guizhifulingwan (GFW) in the treatment of climacteric syndrome in women.</p></sec><sec><title>Methods/design</title><p>This is a single-center, randomized, placebo-controlled, parallel-group design pilot trial. Fifty participants with climacteric syndrome will be randomly allocated to the GFW or placebo group in a 1:1 ratio. The participants will be administered GFW or placebo granules three times a day for 4&#x000a0;weeks and will be followed up for a further 4&#x000a0;weeks. The primary outcome is the mean change in menopause rating scale score at 5&#x000a0;weeks after randomization. Secondary outcomes include the World Health Organization quality of life-BREF scores, degrees of upward movement of qi and lower abdominal resistance and tenderness, blood stasis pattern questionnaire scores, and results of blood tests including assays for lipid profile, high sensitivity C-reactive protein, follicle-stimulating hormone, and estradiol. The feasibility outcomes include recruitment and completion rates and adherence to medication.</p></sec><sec><title>Discussion</title><p>The results of this study will provide basic data for the design of a large-scale clinical trial for evaluating the efficacy of GFW in the treatment of climacteric syndrome in women.</p></sec><sec><title>Trial registration</title><p>Clinical Research Information Service (CRIS), Republic of Korea, <ext-link ext-link-type="uri" xlink:href="https://cris.nih.go.kr/cris/search/search_result_st01_en.jsp?seq=6865&#x00026;ltype=&#x00026;rtype=">KCT0002040</ext-link>. Registered on 5 September 2016.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13063-017-1877-8) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Guizhifulingwan</kwd><kwd>Keishibukuryogan</kwd><kwd>Climacteric syndrome</kwd><kwd>Menopause</kwd><kwd>Randomized controlled trial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Although menopause is a natural phenomenon in women, the accompanying pre- and post-menopausal symptoms can considerably affect their daily activities and quality of life (QOL) [<xref ref-type="bibr" rid="CR1">1</xref>]. Although hormone replacement therapy (HRT) is known to be effective for menopausal symptoms [<xref ref-type="bibr" rid="CR2">2</xref>], it has been reported to increase the incidence of thrombosis, stroke, and ovarian cancer [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Because of concerns regarding the potential adverse events (AEs) associated with HRT, interest in and the use of complementary and alternative medicines related to climacteric symptoms are increasing. Although herbal medicine is among the more commonly used complementary and alternative medicines, there is little evidence supporting its efficacy [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Guizhifulingwan (GFW; Keishibukuryogan in Japanese) has been widely used for centuries in China, Korea, and Japan for gynecological disorders caused by blood stasis [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. It also has been considered effective in the management of climacteric symptoms. The symptoms for which GFW is indicated&#x02014;blood stasis pattern (hot flushes with cold legs, neck ache, and stiffness), solid constitution (not in a physically weakened state), ruddy face, etc.&#x02014; are not necessarily restricted to women in menopausal transition; they are generally regarded as characteristic of women suffering from vasomotor symptoms such as hot flushes and perspiration [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Although recent clinical studies have evaluated the efficacy of GFW in the treatment of menopause-related symptoms [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>], a randomized controlled trial (RCT) for validating the same has not yet been undertaken. Although one of the relevant studies demonstrated a positive outcome in terms of QOL in menopausal women upon treatment with GFW, the study neither included a control group nor described the criteria for blood stasis pattern during participant selection [<xref ref-type="bibr" rid="CR13">13</xref>]. On the other hand, while a previous RCT on hot flushes in menopausal women did not yield a positive outcome in this regard, it described the importance of symptom patterns of each participant in the inclusion criteria [<xref ref-type="bibr" rid="CR16">16</xref>]. We designed this study to better reflect the characteristics of traditional medicine by considering the traditional symptom pattern of GFW in the participant inclusion criteria and assessment methods.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods/design</title><sec id="Sec3"><title>Objective</title><p>The aim of this study is to explore the efficacy of GFW in the treatment of climacteric syndrome in women.</p></sec><sec id="Sec4"><title>Design</title><p>This study will be a randomized, double-blind, controlled, parallel-group pilot trial. Participants will be randomly assigned to the GFW or placebo group in a ratio of 1:1. The study period will be about 8&#x000a0;weeks&#x02014;4&#x000a0;weeks each of medication and follow-up. The design is summarized in Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>. The study protocol (version 1.1, 25 July 2016) follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Study flow chart</p></caption><graphic xlink:href="13063_2017_1877_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>SPIRIT schedule for enrollment, interventions, and assessments</p></caption><graphic xlink:href="13063_2017_1877_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec5"><title>Recruitment</title><p>Participants will be recruited through advertisements in local newspapers, the subway, and our hospital.</p></sec><sec id="Sec6"><title>Participants</title><sec id="Sec7"><title>Inclusion criteria</title><p>Inclusion criteria for the study will be as follows: (1) age, 45&#x02013;60 years; (2) menopausal women (including those with natural or induced menopause) with pre- and post-menopausal climacteric symptoms; (3) menopause rating scale (MRS) [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] score &#x02265;9; (4) moderate to high physical strength; (5) moderate to high degree of upward movement of qi; (6) moderate to high degree of lower abdominal resistance and tenderness; and (7) willingness to provide written informed consent.</p><p>Natural menopause is considered to have occurred after 12 consecutive months of amenorrhea with no other obvious pathological or physiological cause. The term &#x0201c;climacteric&#x0201d; encompasses perimenopause by extending the duration of symptoms for a variable period long before and after menopause. The term &#x0201c;perimenopause&#x0201d; includes the period immediately prior to menopause and the first year after menopause [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>GFW is generally used for those who are not in a physically weakened state [<xref ref-type="bibr" rid="CR10">10</xref>]. The degree of physical strength of inclusion criterion 4 is evaluated by referencing body physique, nutritional status, and the results of exclusion criteria 6 and 7 together, and is scored on a 3-point scale (1&#x02009;=&#x02009;low, 2&#x02009;=&#x02009;moderate, and 3&#x02009;=&#x02009;high).</p></sec><sec id="Sec8"><title>Exclusion criteria</title><p>Exclusion criteria for the study are as follows: (1) serious and unstable medical conditions; (2) severe mental disease; (3) aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and &#x003b3;-glutamyl transpeptidase (&#x003b3;-GTP) levels 1.5 times as high as or higher than the normal upper limit; (4) blood urea nitrogen (BUN) and creatinine (Cr) levels 1.5 times as high as or higher than the normal upper limit; (5) thyroid-stimulating hormone level 1.5 times lower than the normal lower limit; (6) body mass index &#x0003c;18.5; (7) hemoglobin (Hb) level &#x0003c;11&#x000a0;g/dL; (8) estrogen therapy within a year prior to the study; (9) herbal medicine therapy related to climacteric syndrome within 4&#x000a0;weeks prior to the study; (10) vaginal bleeding without cause after menopause; (11) lactose intolerance; (12) participation in other clinical trials; (13) residents of collective dwelling facilities such as social welfare institutions; (14) unwillingness to provide written consent; and (15) participants judged unsuitable for the clinical trial by the investigator.</p></sec></sec><sec id="Sec9"><title>Randomization and allocation concealment</title><p>A statistician will generate random allocation numbers using a computer program (SAS [Strategic Applications Software], version 9.4; SAS Institute Inc., Cary, NC, USA). The generated numbers will be sealed in opaque envelopes and stored in double-locked cabinets. Participants who fulfill all of the inclusion criteria will be assigned to one of two groups by blocked randomization.</p></sec><sec id="Sec10"><title>Blinding</title><p>The participants, investigators, coordinators, pharmacist, monitoring agent, and statistician will be blinded to the group allocation data, which will be known only to the person in charge of random allocation. The statistician will create a random allocation table indicating assignment to group A or B. The person in charge of random allocation will deliver this allocation table and group information to the pharmaceutical company (as there is no one at the investigational products manufacturing company to create a randomization list, our team will prepare the randomization table). The pharmaceutical company will make and label investigational products based on this information. The label will include each participant&#x02019;s identification number (R1001 to R1050; identical to the random allocation numbers) and visit number (V1 or V2). An opaque emergency envelope containing allocation information will be prepared and stored in a safe place in anticipation of unexpected events [<xref ref-type="bibr" rid="CR20">20</xref>]. Violation of blinding will be considered only under circumstances where knowledge of the medication being administered to a participant is essential for treatment. The validity of blinding will be assessed according to the new blinding index [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec11"><title>Intervention</title><p>Participants will be randomly assigned to the GFW or placebo control group in a ratio of 1:1. They will receive treatment or evaluation according to the predetermined schedule. All participants will orally ingest 3&#x000a0;g of granules three times a day for 4&#x000a0;weeks and present themselves for follow-up evaluation 4&#x000a0;weeks after the termination of medication. The drugs for this clinical trial will be provided to the participants twice in 2-week intervals at weeks 1 and 3. To confirm their adherence to the medication regimen, participants will be requested to return unused drugs as well as spent wrappers of used drugs.</p><p>Both GFW and the placebo are manufactured by Hanpoong Pharm. Co., Ltd. (Wanju, Republic of Korea) according to good manufacturing practice standards. Only those products that pass quality control tests will be used in this study. While GFW comprises <italic>Ramulus cinnamomi</italic>, <italic>Poria</italic>, <italic>Moutan cortex</italic>, <italic>Persicae semen</italic>, and <italic>Radix paeoniae</italic> [<xref ref-type="bibr" rid="CR9">9</xref>] (3&#x000a0;g of GFW granules are prepared according to the granulation method using 1.33&#x000a0;g of GFW soft extract, which is prepared by extracting 1.33&#x000a0;g of each of the five herbs [same ratio] with water in an extractor, followed by filtration and concentration), the placebo comprises corn starch, lactose hydrate, citric acid hydrate, ginseng flavor powder, and caramel coloring. Both these drugs are similar in appearance and color (brown) and will be packaged in an identical shape.</p></sec><sec id="Sec12"><title>Concomitant treatment</title><p>Participants of both groups will be prohibited from concomitant use of menopause-related hormone therapy (estrogen, estrogen/progestogen, or tibolone), non-prescription medicines, functional health foods, or Oriental medicines that can potentially affect the outcome of this experiment until after the follow-up period of 8&#x000a0;weeks. Participants who have been on medication for chronic diseases prior to initiation of this study will be allowed to continue their regimen, and care will be taken not to alter the dosage or type of drug. Similarly, participants will be allowed to maintain their pre-trial exercise routines without altering the intensity or type of exercise. If the dosage or type of existing medication or intensity or type of exercise is changed, the participant will be required to report the same to the person in charge of this study.</p></sec><sec id="Sec13"><title>Outcome measurements</title><p>The time points for the outcome measurements are presented in detail in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.</p><sec id="Sec14"><title>Primary outcome</title><p>The primary outcome is the mean change in MRS score at week 5. The MRS comprises 11 items encompassing 3 subscales: psychological, somato-vegetative, and urogenital domains. Each item is scored on a 4-point scale, with scores ranging from 0 (no symptoms) to 4 (very severe). Based on the total score, determined by the sum of the scores of the subscales, the degree of symptoms can be classified as follows: &#x0201c;no, little&#x0201d; (0&#x02013;4), &#x0201c;mild&#x0201d; (5&#x02013;8), &#x0201c;moderate&#x0201d; (9&#x02013;16), and &#x0201c;severe&#x0201d; (&#x0003e;17) [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The Korean version of the MRS will be used in the present study (<ext-link ext-link-type="uri" xlink:href="http://www.menopause-rating-scale.info/">http://www.menopause-rating-scale.info</ext-link>).</p></sec><sec id="Sec15"><title>Secondary outcomes</title><sec id="FPar1"><title>World Health Organization QOL-BREF (WHOQOL-BREF)</title><p>The WHOQOL-BREF comprises 26 questions including 24 questions regarding 4 sub-sections&#x02014;physical and psychological health, social relationship, and environment&#x02014;and 2 questions regarding overall QOL. Each item is scored on a 5-point scale as follows: 1, strongly disagree; 2, disagree; 3, neutral; 4, agree; and 5, strongly agree. The Korean version of the WHOQOL-BREF will be used in the present study [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="FPar2"><title>Degree of upward movement of qi</title><p>The degree of upward movement of qi is evaluated by scoring symptoms corresponding to each of five body parts on a 5-point scale (1, no symptoms; 2, mild; 3, moderate; 4, severe; and 5, extreme). The sum of these scores is divided by 5 to obtain the final value for analysis. If the final value is a decimal, it is rounded off to one decimal place. The five body parts and their corresponding symptoms are as follows: head (headache, dizziness, and heavy-headedness); face (ruddy face and hot flushes); shoulders (neck and shoulder stiffness); chest (flushing sensation and palpitation); and lower limbs (cold legs and feet). These symptoms have been identified based on previous reports [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], and the scoring method has been devised by the research team involved in this study.</p></sec><sec id="FPar3"><title>Degree of lower abdominal resistance and tenderness</title><p>Abdominal examination will be performed according to the following protocol. The practitioner&#x02019;s hands should be sufficiently warm before beginning the examination. The room itself should be warm enough that the participant does not shiver or become tense. The participant lies supine, comfortably, with both legs extended. When necessary, the exam can be conducted with both knees bent. The practitioner stands on the right (or left) side of the participant and first observes the entire abdomen and then palpates the lower abdomen while trying not to apply more pressure than necessary [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The abdominal exam is performed from top to bottom and left to right. The abdominal symptoms of GFW include a resistance that feels like a palpable mass-like object in the lower abdomen. Tenderness is not severe [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. The degree of lower abdominal resistance and tenderness is scored on a 5-point scale (1, none; 2, mild; 3, moderate; 4, severe; and 5, extreme).</p></sec><sec id="FPar4"><title>Questionnaire for blood stasis pattern</title><p>The questionnaire for blood stasis pattern comprises 14 items: sprain; contusion; old BiJeung (BiJeung shows symptoms similar to those of arthralgia and paresthesia syndrome [<xref ref-type="bibr" rid="CR28">28</xref>]); stabbing pain; lower abdominal pain; hypochondriac pain; night pain; feeling of abdominal mass; easy congealing of blood; darkish complexion (discoloration of the face); purple and dull pallor of the mouth, lips, and tongue; bluish purple discoloration of the lower eyelid; darkish stools; and number of surgeries. Each item is scored on a 7-point scale [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="FPar5"><title>Blood tests</title><p>Blood tests including those for internal lipid (low-density lipoprotein, high-density lipoprotein, total cholesterol, and triglycerides), high sensitivity C-reactive protein (for prediction of risk of cardiovascular diseases [<xref ref-type="bibr" rid="CR30">30</xref>]), and hormone (follicle-stimulating hormone and estradiol, for understanding the climacteric condition) levels will be conducted.</p></sec></sec><sec id="Sec16"><title>Feasibility outcomes</title><sec id="FPar6"><title>Recruitment rate</title><p>The recruitment rate will be calculated as the percentage of participants selected from among those who undergo screening and the percentage of participants selected against the total number of participants.</p></sec><sec id="FPar7"><title>Completion rate</title><p>The completion rate will be calculated as the percentage of participants who complete the study without interruption until the endpoint against the total number of participants.</p></sec><sec id="FPar8"><title>Medication adherence</title><p>Medication adherence will be calculated as the percentage of doses ingested by the participants against the total dose.</p></sec></sec><sec id="Sec17"><title>Safety and adverse event outcomes</title><p>Adverse events (AEs) indicate undesirable and unintentional signs, symptoms, or diseases that develop after intervention during the period of a clinical trial. They do not necessarily have a causal relationship with the relevant intervention. Investigators will check participants&#x02019; vital signs and examine for manifestation of AEs, including digestive symptoms, skin conditions, and jaundice, at every visit. Investigators will also conduct physical examination and laboratory tests, including evaluation of AST, ALT, ALP, &#x003b3;-GTP, BUN, Cr, Hb, and hematocrit levels and red and white blood cell, differential, and platelet counts, at the screening as well as at the fourth visit (week 9). In case of AEs, the correlation between AEs and intervention will be classified into one of the following six categories: (1) definitely related, (2) appears to be related, (3) possibly related, (4) appears to be unrelated, (5) definitely not related, or (6) unclear.</p></sec></sec><sec id="Sec18"><title>Sample size</title><p>The null hypothesis (<italic>H</italic>
<sub><italic>0</italic></sub>) of this study is that there will be no difference in the mean change in MRS scores between the GFW and placebo groups after 4&#x000a0;weeks of medication. The alternative hypothesis (<italic>H</italic>
<sub><italic>1</italic></sub>) is the opposite scenario of <italic>H</italic>
<sub><italic>0</italic></sub>. In the GFW group of a previous study [<xref ref-type="bibr" rid="CR13">13</xref>], the mean change in MRS scores from baseline to day 30 was &#x02212;7.27; the authors determined the mean change in MRS scores of the control group to be &#x02212;1.45 under the assumption that it would correspond to approximately 20% of the value observed with the treatment group. With this previous study [<xref ref-type="bibr" rid="CR13">13</xref>] as a reference, we assumed that the standard deviation of change in MRS scores from baseline to week 4 will be 6.73. With a 5% significance level and 80% power, the sample size was determined to be 21 participants per group:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \mathrm{n}\kern0.5em =\kern0.5em \frac{2{\left({z}_{a/2}+{z}_{\beta}\right)}^2{\sigma}^2}{\delta^2}\kern0.5em =\kern0.5em \frac{2{\left(1.96\kern0.5em +\kern0.5em 0.84\right)}^2\kern0.5em {(6.73)}^2}{{\left(-5.82\right)}^2}\kern0.5em 20.97\approx 21 $$\end{document}</tex-math><mml:math id="M2"><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="0.5em"/><mml:mo>=</mml:mo><mml:mspace width="0.5em"/><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo stretchy="true">/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>&#x003b2;</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:msup><mml:mi>&#x003b4;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mfrac><mml:mspace width="0.5em"/><mml:mo>=</mml:mo><mml:mspace width="0.5em"/><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1.96</mml:mn><mml:mspace width="0.5em"/><mml:mo>+</mml:mo><mml:mspace width="0.5em"/><mml:mn>0.84</mml:mn></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mspace width="0.5em"/><mml:msup><mml:mfenced close=")" open="("><mml:mn>6.73</mml:mn></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>5.82</mml:mn></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mfrac><mml:mspace width="0.5em"/><mml:mn>20.97</mml:mn><mml:mo>&#x02248;</mml:mo><mml:mn>21</mml:mn></mml:math><graphic xlink:href="13063_2017_1877_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
</p><p>Considering a 15% dropout rate, we determined that 25 participants will be ideally required per group.</p></sec><sec id="Sec19"><title>Statistical analysis</title><p>The analysis set will comprise a full analysis set (FAS) and a per-protocol set (PPS). The FAS will include participants who satisfy the intention-to-treat principle as completely as possible. The PPS will include participants who are more compliant with the study protocol [<xref ref-type="bibr" rid="CR31">31</xref>]. The FAS will be used for the main analysis. Analysis of covariance will be performed to evaluate the values of outcomes at weeks 5 and 9 as dependent variables, the baseline values as covariates, and the group as a constant. Participants will be divided into pre- and post-menopausal groups, which will be evaluated by exploratory subgroup analysis according to MRS scores in order to determine whether the intervention is equally effective on both subgroups. Intra-group comparisons will be performed by the paired <italic>t</italic> test or Wilcoxon signed-rank test. The analyses will be performed considering an &#x003b1;-value of 5% and a power of 80%. Missing data will be imputed by multiple imputation. For socio-demographic characteristics, continuous variables will be presented as mean value and standard deviation, while categorical variables will be presented as frequency and percentage. Statistical analysis will be performed using the SAS program (version 9.4; SAS Institute Inc., Cary, NC, USA).</p></sec><sec id="Sec20"><title>Data and safety monitoring</title><p>The trial data will be saved in an electronic data capture system (Medidata Rave; Medidata Solutions Inc., New York, NY, USA). Data quality will be ensured by regular monitoring. The monitoring agent will confirm whether the data are consistent with the source documents and whether the trial is conducted according to the approved protocol. All AEs observed during the study period will be recorded and reported.</p></sec></sec><sec id="Sec21" sec-type="discussion"><title>Discussion</title><p>The purpose of this study is to explore the efficacy of GFW in the treatment of climacteric syndrome in women with blood stasis pattern. The study will also serve to monitor the safety of GFW.</p><p>Traditional Chinese medicine (TCM) has been adopted in a modified form in East Asian countries such as Japan and Korea [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. The system of pattern identification&#x02014;the process of overall analysis of clinical data to determine the location, cause, and nature of disease in a patient and diagnosing a pattern/syndrome [<xref ref-type="bibr" rid="CR34">34</xref>]&#x02014;practiced in the three countries varies to a certain extent. In TCM, a practitioner recognizes the &#x0201c;Zheng&#x0201d; (clinical diagnosis based on analysis of medical history, symptoms, and signs) and confirms the treatment principle. In traditional Japanese medicine (Kampo), a practitioner chooses the most appropriate formula from among approximately 150 ready-to-use formulas, according to the &#x0201c;Sho&#x0201d; (pattern of symptoms) of the patient [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Kampo can be characterized as a simplified and pragmatic version of Chinese herbal medicine [<xref ref-type="bibr" rid="CR36">36</xref>]. In traditional Korean medicine (TKM), disease and pattern identification are made simultaneously as described in<italic> Dongui Bogam</italic> [<xref ref-type="bibr" rid="CR37">37</xref>], which was compiled in the 17th century. TKM has been developed to include various modified methods involving the application of existing principles, methods, and formulas [<xref ref-type="bibr" rid="CR38">38</xref>]. The diagnostic system of TKM includes the determination of diagnostic criteria based on indications for prescription of herbal medicines for a certain disease or its etiology [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. Standardization of diverse pattern identification systems has been inadequate until now, which has made it challenging to apply pattern identification to clinical research on traditional medicine [<xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. For the findings of clinical studies to be of direct aid in medical decision-making in traditional clinical practice, pattern identification systems used in routine practice need to be accurately reflected in the study design [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The present trial was planned in consideration of the target symptoms for herbal formulas, with Western medical methods for participant selection and outcome measurement. This approach is in agreement with a previous proposal for complementation of clinical research methods in traditional medicine [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p>Although the pattern identification and outcome measurement methods of this study are not ideal, they could serve as a reference for planning clinical trials that reflect the characteristics of traditional medicine. The results of this study will provide basic data for the designing of a large-scale trial evaluating the efficacy of GFW for the treatment of climacteric syndrome in women.</p><sec id="Sec22"><title>Trial status</title><p>Recruitment began in mid-October 2016.</p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec23"><title>Additional file</title><p>
<media position="anchor" xlink:href="13063_2017_1877_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>SPIRIT 2013 checklist. (DOCX 51 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>AE</term><def><p>Adverse event</p></def></def-item><def-item><term>ALP</term><def><p>Alkaline phosphatase</p></def></def-item><def-item><term>ALT</term><def><p>Alanine aminotransferase</p></def></def-item><def-item><term>ANCOVA</term><def><p>Analysis of covariance</p></def></def-item><def-item><term>AST</term><def><p>Aspartate aminotransferase</p></def></def-item><def-item><term>BUN</term><def><p>Blood urea nitrogen</p></def></def-item><def-item><term>Cr</term><def><p>Creatinine</p></def></def-item><def-item><term>E2</term><def><p>Estradiol</p></def></def-item><def-item><term>EDC</term><def><p>Electronic data capture</p></def></def-item><def-item><term>FAS</term><def><p>Full analysis set</p></def></def-item><def-item><term>FSH</term><def><p>Follicle-stimulating hormone</p></def></def-item><def-item><term>GFW</term><def><p>Guizhifulingwan</p></def></def-item><def-item><term>GMP</term><def><p>Good manufacturing practice</p></def></def-item><def-item><term>GTP</term><def><p>Glutamyl transpeptidase</p></def></def-item><def-item><term>Hb</term><def><p>Hemoglobin</p></def></def-item><def-item><term>Hct</term><def><p>Hematocrit</p></def></def-item><def-item><term>HRT</term><def><p>Hormone replacement therapy</p></def></def-item><def-item><term>Hs-CRP</term><def><p>High sensitivity C-reactive protein</p></def></def-item><def-item><term>ITT</term><def><p>Intention-to-treat</p></def></def-item><def-item><term>MRS</term><def><p>Menopause rating scale</p></def></def-item><def-item><term>PPS</term><def><p>Per-protocol set</p></def></def-item><def-item><term>RBC</term><def><p>Red blood cell</p></def></def-item><def-item><term>RCT</term><def><p>Randomized controlled trial</p></def></def-item><def-item><term>SAS</term><def><p>Strategic Applications Software</p></def></def-item><def-item><term>SPIRIT</term><def><p>Standard Protocol Items: Recommendations for Interventional Trials</p></def></def-item><def-item><term>TCM</term><def><p>Traditional Chinese medicine</p></def></def-item><def-item><term>TKM</term><def><p>Traditional Korean medicine</p></def></def-item><def-item><term>WBC</term><def><p>White blood cell</p></def></def-item><def-item><term>WHOQOL</term><def><p>World Health Organization quality of life</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar9"><title>Funding</title><p>This study is supported by the Korea Institute of Oriental Medicine (K17121). The funder has no role in the design of the study, the collection, analysis, and interpretation of data, the writing of the manuscript, or the decision to submit the manuscript for publication.</p></sec><sec id="FPar10"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec id="FPar11"><title>Authors&#x02019; contributions</title><p>JEK conceived and planned the study protocol and drafted the manuscript. JHC, JHK, MKK, and HYL participated in the design of the outcome measurements and helped to draft the manuscript. OJK planned the statistical design of the study and wrote part of the statistical methods. ARK, HJP, and SYJ provided technical advice and contributed to critical revision of the manuscript. JHL participated in the overall design of the study, provided critical revision of the manuscript, and had the final responsibility for the decision to submit for publication. All authors read and approved the final manuscript.</p></sec><sec id="FPar12"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar13"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar14"><title>Ethics approval and consent to participate</title><p>This study has been approved by the institutional review boards of the Daejeon Oriental Hospital of Daejeon University (djomc-138-1). Written informed consent will be obtained from all participants by the investigator.</p></sec><sec id="FPar15"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poomalar</surname><given-names>GK</given-names></name><name><surname>Arounassalame</surname><given-names>B</given-names></name></person-group><article-title>The quality of life during and after menopause among rural women</article-title><source>J Clin Diagn Res</source><year>2013</year><volume>7</volume><fpage>135</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1752-699X.2012.00294.x</pub-id><pub-id pub-id-type="pmid">23450244</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>North American Menopause Society</collab></person-group><article-title>The 2012 hormone therapy position statement of the North American Menopause Society</article-title><source>Menopause</source><year>2012</year><volume>19</volume><fpage>257</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1097/gme.0b013e31824b970a</pub-id><pub-id pub-id-type="pmid">22367731</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Boardman HM, Hartley L, Eisinga A, Main C, Roqu&#x000e9; i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015:CD002229; doi: 10.1002/14651858.CD002229.pub4.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Collaborative Group on Epidemiological Studies Of Ovarian Cancer</collab><name><surname>Beral</surname><given-names>V</given-names></name><name><surname>Gaitskell</surname><given-names>K</given-names></name><name><surname>Hermon</surname><given-names>C</given-names></name><name><surname>Moser</surname><given-names>K</given-names></name><name><surname>Reeves</surname><given-names>G</given-names></name><etal/></person-group><article-title>Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies</article-title><source>Lancet</source><year>2015</year><volume>385</volume><fpage>1835</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61687-1</pub-id><pub-id pub-id-type="pmid">25684585</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posadzki</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Moon</surname><given-names>TW</given-names></name><name><surname>Choi</surname><given-names>TY</given-names></name><name><surname>Park</surname><given-names>TY</given-names></name><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>Prevalence of complementary and alternative medicine (CAM) use by menopausal women: a systematic review of surveys</article-title><source>Maturitas</source><year>2013</year><volume>75</volume><fpage>34</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2013.02.005</pub-id><pub-id pub-id-type="pmid">23497959</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrelli</surname><given-names>F</given-names></name><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>Alternative and complementary therapies for the menopause</article-title><source>Maturitas</source><year>2010</year><volume>66</volume><fpage>333</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2010.05.010</pub-id><pub-id pub-id-type="pmid">20580501</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>WJ</given-names></name></person-group><article-title>What has been overlooked on study of Chinese materia medica in the West?</article-title><source>Chin J Integr Med</source><year>2015</year><volume>21</volume><fpage>483</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s11655-015-2081-x</pub-id><pub-id pub-id-type="pmid">26156100</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Jung</surname><given-names>WS</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name></person-group><article-title>Effect of Gui-zhi-fu-ling-wan on hot flashes in young patients: a retrospective case series</article-title><source>J Acupunct Meridian Stud</source><year>2011</year><volume>4</volume><fpage>129</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S2005-2901(11)60019-8</pub-id><pub-id pub-id-type="pmid">21704956</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Cheon</surname><given-names>CH</given-names></name><name><surname>Jo</surname><given-names>SC</given-names></name><name><surname>Cho</surname><given-names>HB</given-names></name><name><surname>Lim</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Effects and safety of gyejibongnyeong-hwan on dysmenorrhea caused by blood stagnation: a randomized controlled trial</article-title><source>Evid Based Complement Alternat Med</source><year>2013</year><volume>2013</volume><fpage>424730</fpage><pub-id pub-id-type="pmid">24191165</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshino</surname><given-names>T</given-names></name><name><surname>Katayama</surname><given-names>K</given-names></name><name><surname>Horiba</surname><given-names>Y</given-names></name><name><surname>Munakata</surname><given-names>K</given-names></name><name><surname>Yamaguchi</surname><given-names>R</given-names></name><name><surname>Imoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>The difference between the two representative Kampo formulas for treating dysmenorrhea: an observational study</article-title><source>Evid Based Complement Alternat Med</source><year>2016</year><volume>2016</volume><fpage>3159617</fpage><pub-id pub-id-type="doi">10.1155/2016/3159617</pub-id><pub-id pub-id-type="pmid">27006676</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terauchi</surname><given-names>M</given-names></name><name><surname>Hiramitsu</surname><given-names>S</given-names></name><name><surname>Akiyoshi</surname><given-names>M</given-names></name><name><surname>Owa</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Obayashi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of three Kampo formulae: Tokishakuyakusan (TJ-23), Kamishoyosan (TJ-24), and Keishibukuryogan (TJ-25) on Japanese peri- and postmenopausal women with sleep disturbances</article-title><source>Arch Gynecol Obstet</source><year>2011</year><volume>284</volume><fpage>913</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s00404-010-1779-4</pub-id><pub-id pub-id-type="pmid">21120510</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terauchi</surname><given-names>M</given-names></name><name><surname>Akiyoshi</surname><given-names>M</given-names></name><name><surname>Owa</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Obayashi</surname><given-names>S</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name></person-group><article-title>Effects of the Kampo medication keishibukuryogan on blood pressure in perimenopausal and postmenopausal women</article-title><source>Int J Gynaecol Obstet</source><year>2011</year><volume>114</volume><fpage>149</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.ijgo.2011.03.006</pub-id><pub-id pub-id-type="pmid">21669429</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JM</given-names></name><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>DI</given-names></name></person-group><article-title>A clinical trial to verify the quality of life improvement efficacy of Dangguijakyak-san and Gyejibongnyeong-hwan granulation in postmenopausal women</article-title><source>J Orient Obstet Gynecol</source><year>2007</year><volume>20</volume><fpage>213</fpage><lpage>28</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ushiroyama</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>A</given-names></name><name><surname>Sakuma</surname><given-names>K</given-names></name><name><surname>Ueki</surname><given-names>M</given-names></name></person-group><article-title>Comparing the effects of estrogen and an herbal medicine on peripheral blood flow in post-menopausal women with hot flashes: hormone replacement therapy and gui-zhi-fu-ling-wan, a Kampo medicine</article-title><source>Am J Chin Med</source><year>2005</year><volume>33</volume><fpage>259</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1142/S0192415X05002813</pub-id><pub-id pub-id-type="pmid">15974485</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namiki</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Kakikura</surname><given-names>H</given-names></name><name><surname>Ueno</surname><given-names>K</given-names></name><name><surname>Chino</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of a predictive biomarker for the beneficial effect of keishibukuryogan, a Kampo (Japanese traditional) medicine, on patients with climacteric syndrome</article-title><source>Evid Based Complement Alternat Med</source><year>2014</year><volume>2014</volume><fpage>962109</fpage><pub-id pub-id-type="doi">10.1155/2014/962109</pub-id><pub-id pub-id-type="pmid">24639885</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotnikoff</surname><given-names>GA</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Torkelson</surname><given-names>C</given-names></name><name><surname>La Valleur</surname><given-names>J</given-names></name><name><surname>Radosevich</surname><given-names>DM</given-names></name></person-group><article-title>The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women: results and lessons for future research</article-title><source>Menopause</source><year>2011</year><volume>18</volume><fpage>886</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1097/gme.0b013e31821643d9</pub-id><pub-id pub-id-type="pmid">21738077</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>GA</given-names></name><name><surname>Huber</surname><given-names>IC</given-names></name><name><surname>Keller</surname><given-names>PJ</given-names></name><name><surname>Lauritzen</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>HPG</given-names></name></person-group><article-title>Evaluation der klinischen Beschwerden (Menopause Rating Scale)</article-title><source>Zentralbl Gynakol</source><year>1994</year><volume>116</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">8147175</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potthoff</surname><given-names>P</given-names></name><name><surname>Heinemann</surname><given-names>LAJ</given-names></name><name><surname>Schneider</surname><given-names>HPG</given-names></name><name><surname>Rosemeier</surname><given-names>HP</given-names></name><name><surname>Hauser</surname><given-names>GA</given-names></name></person-group><article-title>Menopause-Rating Skala (MRS): Methodische Standardisierung in der deutschen Bev&#x000f6;lkerung</article-title><source>Zentralbl Gynakol</source><year>2000</year><volume>122</volume><fpage>280</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10857215</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">International Menopause Society. Menopause terminology. <ext-link ext-link-type="uri" xlink:href="http://www.imsociety.org/menopause_terminology.php">http://www.imsociety.org/menopause_terminology.php</ext-link>. Accessed 20 June 2016.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Witt</surname><given-names>CM</given-names></name><name><surname>Linde</surname><given-names>K</given-names></name></person-group><source>Clinical research in complementary and integrative medicine: a practical training book</source><year>2013</year><edition>1</edition><publisher-loc>Seoul</publisher-loc><publisher-name>Elsevier Korea</publisher-name></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>HJ</given-names></name><name><surname>Ni</surname><given-names>LY</given-names></name><name><surname>Davis</surname><given-names>CE</given-names></name></person-group><article-title>Assessment of blinding in clinical trials</article-title><source>Control Clin Trials</source><year>2004</year><volume>25</volume><fpage>143</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.cct.2003.10.016</pub-id><pub-id pub-id-type="pmid">15020033</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The WHOQOL Group</collab></person-group><article-title>Development of the World Health Organization WHOQOL-BREF quality of life assessment</article-title><source>Psychol Med</source><year>1998</year><volume>28</volume><fpage>551</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1017/S0033291798006667</pub-id><pub-id pub-id-type="pmid">9626712</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>CI</given-names></name><name><surname>Kim</surname><given-names>KI</given-names></name><name><surname>Suh</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name></person-group><article-title>Development of Korean version of WHO quality of life scale abbreviated version (WHOQOL-BREF)</article-title><source>J Korean Neuropsychiatr Assoc</source><year>2000</year><volume>39</volume><fpage>571</fpage><lpage>9</lpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Min</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>KI</given-names></name><name><surname>Park</surname><given-names>IH</given-names></name></person-group><source>Korean version of WHOQOL</source><year>2002</year><edition>1</edition><publisher-loc>Seoul</publisher-loc><publisher-name>Hana Medical Press</publisher-name></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shigetaro</surname><given-names>K</given-names></name></person-group><source>Abdominal examination and prescription</source><year>2014</year><edition>2</edition><publisher-loc>Wonju</publisher-loc><publisher-name>Uibang Press</publisher-name></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Roh</surname><given-names>YB</given-names></name></person-group><source>Abdominal examination and authentic prescription</source><year>2006</year><edition>1</edition><publisher-loc>Goyang</publisher-loc><publisher-name>Daesung Medical Press</publisher-name></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group><source>Kampo treatment for climacteric disorders</source><year>1997</year><edition>1</edition><publisher-loc>Brookline</publisher-loc><publisher-name>Paradigm Publications</publisher-name></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>YB</given-names></name></person-group><article-title>Developing questionnaire of BiJeung (&#x075fa;&#x08b49;) which is similar to arthralgia and paresthesia syndrome</article-title><source>J Korean Med</source><year>2013</year><volume>34</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.13048/jkm.13015</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>YB</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name></person-group><article-title>Development of questionnaires for blood stasis pattern</article-title><source>J Korean Orient Med Diagn</source><year>2006</year><volume>10</volume><fpage>141</fpage><lpage>52</lpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>SM</given-names></name><name><surname>Baek</surname><given-names>SH</given-names></name><name><surname>Jeon</surname><given-names>HK</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Correlations between the level of high-sensitivity C-reactive protein and cardiovascular risk factors in Korean adults with cardiovascular disease or diabetes mellitus: the CALLISTO study</article-title><source>J Atheroscler Thromb</source><year>2013</year><volume>20</volume><fpage>616</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.5551/jat.16089</pub-id><pub-id pub-id-type="pmid">23676341</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JA</given-names></name></person-group><article-title>Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline</article-title><source>Stat Med</source><year>1999</year><volume>18</volume><fpage>1903</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19990815)18:15&#x0003c;1903::AID-SIM188&#x0003e;3.0.CO;2-F</pub-id><pub-id pub-id-type="pmid">10440877</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Moriya</surname><given-names>J</given-names></name><name><surname>Kawaura</surname><given-names>K</given-names></name><name><surname>Yamakawa</surname><given-names>J</given-names></name><name><surname>Kusaka</surname><given-names>K</given-names></name><etal/></person-group><article-title>Traditional Chinese medicine and Kampo: a review from the distant past for the future</article-title><source>J Int Med Res</source><year>2006</year><volume>34</volume><fpage>231</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/147323000603400301</pub-id><pub-id pub-id-type="pmid">16866016</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>What&#x02019;s in a name? A systematic review of the nomenclature of Chinese medical formulae</article-title><source>Am J Chin Med</source><year>2002</year><volume>30</volume><fpage>419</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1142/S0192415X02000430</pub-id><pub-id pub-id-type="pmid">12230030</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO Regional Office for the Western Pacific</collab></person-group><source>WHO International Standard Terminologies on Traditional Medicine in the Western Pacific Region</source><year>2007</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>V</given-names></name><name><surname>Ward</surname><given-names>T</given-names></name><name><surname>Cha</surname><given-names>WS</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Liao</surname><given-names>X</given-names></name></person-group><article-title>The treatment of menopausal symptoms by traditional East Asian medicines: review and perspectives</article-title><source>Maturitas</source><year>2010</year><volume>66</volume><fpage>111</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2009.11.020</pub-id><pub-id pub-id-type="pmid">20079585</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terasawa</surname><given-names>K</given-names></name></person-group><article-title>Evidence-based reconstruction of Kampo medicine: Part I&#x02014;Is Kampo CAM?</article-title><source>Evid Based Complement Alternat Med</source><year>2004</year><volume>1</volume><fpage>11</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/ecam/neh003</pub-id><pub-id pub-id-type="pmid">15257321</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>J</given-names></name></person-group><source>Translated Dongui Bogam</source><year>1999</year><edition>1</edition><publisher-loc>Seoul</publisher-loc><publisher-name>Bubin Publishers Co.</publisher-name></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>GY</given-names></name></person-group><article-title>A research on it&#x02019;s teaching way for efficient lecture about differential diagnostic theory and method</article-title><source>Korean J Orient Physiol Pathol</source><year>1998</year><volume>12</volume><fpage>8</fpage><lpage>13</lpage></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>KY</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Choi</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>CY</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Jeon</surname><given-names>CY</given-names></name></person-group><article-title>Study on the proposals for clinical research in Korean medicine worldwide &#x02014; future clinical research strategy II</article-title><source>J Physiol Pathol Korean Med</source><year>2015</year><volume>29</volume><fpage>115</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.15188/kjopp.2015.04.29.2.115</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SD</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Jung</surname><given-names>CY</given-names></name><name><surname>Shin</surname><given-names>KM</given-names></name><name><surname>Jang</surname><given-names>MK</given-names></name><name><surname>Yoon</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Selection of adequate indicators for the development of a questionnaire to evaluate the effects of Ojeock-san</article-title><source>J Korean Orient Med</source><year>2010</year><volume>31</volume><fpage>101</fpage><lpage>14</lpage></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>BS</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Han</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name></person-group><article-title>The basic study for building the depression prescription guideline of Gamiguibi-Tang &#x02014; the evaluation of reliability and validity of the depression pattern-identification questionnaire</article-title><source>J Orient Neuropsychiatry</source><year>2009</year><volume>20</volume><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>JS</given-names></name><name><surname>Oh</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Park</surname><given-names>YB</given-names></name></person-group><article-title>Developing questionnaire for pathogenesis analysis of Pyungweesan symptom</article-title><source>J Korean Orient Med Diagn</source><year>2007</year><volume>11</volume><fpage>72</fpage><lpage>81</lpage></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>ES</given-names></name><name><surname>Kim</surname><given-names>YY</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Yoo</surname><given-names>HR</given-names></name><name><surname>Jung</surname><given-names>IC</given-names></name></person-group><article-title>Review on the development state and utilization of pattern identification questionnaire in Korean medicine by U code of Korean Classification of Disease</article-title><source>J Physiol Pathol Korean Med</source><year>2016</year><volume>30</volume><fpage>124</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.15188/kjopp.2016.04.30.2.124</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>KY</given-names></name><name><surname>Go</surname><given-names>HY</given-names></name><name><surname>Sun</surname><given-names>SH</given-names></name><name><surname>Jeong</surname><given-names>JJ</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Song</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Study on the current situation and issues for clinical research in Korean medicine worldwide &#x02014; future clinical research strategy I. Korean</article-title><source>J Orient Physiol Pathol</source><year>2014</year><volume>28</volume><fpage>137</fpage><lpage>45</lpage></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Matsuura</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Hottenbacher</surname><given-names>L</given-names></name><name><surname>Tokunaga</surname><given-names>H</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Traditional Japanese Kampo medicine: clinical research between modernity and traditional medicine&#x02014;the state of research and methodological suggestions for the future</article-title><source>Evid Based Complement Alternat Med</source><year>2011</year><volume>2011</volume><fpage>513842</fpage><pub-id pub-id-type="doi">10.1093/ecam/neq067</pub-id><pub-id pub-id-type="pmid">21687585</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shea</surname><given-names>JL</given-names></name></person-group><article-title>Applying evidence-based medicine to traditional Chinese medicine: debate and strategy</article-title><source>J Altern Complement Med</source><year>2006</year><volume>12</volume><fpage>255</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1089/acm.2006.12.255</pub-id><pub-id pub-id-type="pmid">16646724</pub-id></element-citation></ref></ref-list></back></article>